You are here
Home > Medical Calculator > Glaucoma BAK-free and PF drops

Medical Treatment of Glaucoma

Exploring BAK-free and Preservative-free options

Ocular tolerance

Key points

  • The goal of topical therapies is to preserve visual function by lowering intraocular pressure (IOP) below a level that is likely to produce further damage to the optic nerve.
  • The growth in available agents for the medical treatment of glaucoma has increased dramatically over the years.
  • It is important to note that no individual medication can be used in all patients in all circumstances.  The goals of therapy are preserving function with the lowest risk, fewest adverse or undesirable effects, and least disruption of the patient's life.
  • An initial reduction in the intraocular pressure of 20% from baseline is suggested.
  •  Patients with more advanced disease on initial presentation require lower initial reductions to prevent further progression and vision loss.
  • The reduction of IOP to the target pressure range does not guarantee that progression will not occur. Therefore, the target pressure range needs to be constantly reassessed and changed as dictated by IOP fluctuations, optic nerve changes, and/or visual field progression.
  • Generic versions of these topical products do not have to prove bioequivalence or equal effectiveness. Data is generally not available for guidance on selection.
  • Topically administered glaucoma medications can have significant systemic absorption.  Patients must be instructed on the proper administration techniques to reduce the risk of systemic adverse effects.

Using this program

The program will provide a list of medications for a particular group, common side effects, and other comments that help with selection of a particular product.

Select 'Yes' for additional info

Preservative-Free options:

BAK-Free Products (not preservative-free)



  1. Aung T, Chan YH, Chew PT, et al. Degree of angle closure and the intraocular pressure-lowering effect of latanoprost in subjects with chronic angle closure glaucoma. Ophthalmology 2005;112:267-71.
  2. Chabi A, Varma R, Tsai JC, et al. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2012;153:1187-96.
  3. Fingeret M, Gaddie IB, Bloomenstein M. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension. Clin Exp Optom. 2019;102(6):541-550. doi:10.1111/cxo.12853.
  4. Fraunfelder FT, Bagby GC. Possible hematologic reactions associated to carbonic anhydrase inhibitors. JAMA 1989;261:2257.
  5. Fraunfelder FT, Meyer SM. Systemic adverse reactions in glaucoma medications [review]. Int Ophthalmol Clin 1989;29:143-6.
  6. Katz LJ, Cohen JS, Batoosingh AL, et al. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol 2010;149:661-71.
  7. Krupin T, Liebmann JM, Greenfield DS, et al. Low-Pressure Glaucoma Study Group. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 2011;151:671-81.
  8. Lewis RA, Katz G, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma 2007;16:98-103.
  9. Li T, Lindsley K, Rouse B, et al. Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis. Ophthalmology. 2016;123(1):129-140. doi:10.1016/j.ophtha.2015.09.005
  10. Lippa EA, Carlson LE, Ehinger B, et al. Dose-response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol 1992;100:495.
  11. Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol 2004;138:389-95.
  12. Parrish RK, Palmberg P, Sheu WP, et al. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703.
  13. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2006;124:1230-8.
  14. Strahlman ER, Tipping R, Vogel R. A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Am J Ophthalmol 1996;122:183-94.
  15. Thygesen J. Glaucoma therapy: preservative-free for all?. Clin Ophthalmol. 2018;12:707-717. Published 2018 Apr 13. doi:10.2147/OPTH.S150816



Ophthalmology Related Tables and Apps



Latest Research


Glaucoma  BAK-free and PF drops